CompletedPhase 2NCT00006028
Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy
Studying Malignant non-epithelial tumor of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gynecologic Oncology Group
- Principal Investigator
- Cheryl A. Brewer, MDUniversity of Illinois College of Medicine at Peoria
- Intervention
- cisplatin(drug)
- Eligibility
- FEMALE
- Timeline
- 2001
Study locations (30)
- Community Hospital of Los Gatos, Los Gatos, California, United States
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
- Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
- University of Chicago Cancer Research Center, Chicago, Illinois, United States
- Indiana University Cancer Center, Indianapolis, Indiana, United States
- Ellis Fischel Cancer Center, Indianapolis, Indiana, United States
- Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
- Tuft-New England Medical Center, Boston, Massachusetts, United States
- University of Mississippi Medical Center, Jackson, Mississippi, United States
- Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States
- Cooper Hospital/University Medical Center, Camden, New Jersey, United States
- State University of New York Health Science Center at Brooklyn, Brooklyn, New York, United States
- Roswell Park Cancer Institute, Buffalo, New York, United States
- State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00006028 on ClinicalTrials.govOther trials for Malignant non-epithelial tumor of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07189871177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsRadiopharm Theranostics, Ltd
- RECRUITINGPHASE1NCT07216105FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid TumorsFate Therapeutics
- RECRUITINGPHASE1NCT06238479A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsEli Lilly and Company
- ACTIVE NOT RECRUITINGPHASE2NCT06169124Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell TumorsNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT05872204Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian CancerUniversitaire Ziekenhuizen KU Leuven
- RECRUITINGPHASE2NCT04644289WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOCAGO Research GmbH
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04180371Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionBicycleTx Limited
See all trials for Malignant non-epithelial tumor of ovary →